VANCOUVER, BRITISH COLUMBIA--(CCNMatthews - Dec. 20, 2005) - WEX Pharmaceuticals Inc. (“WEX” or “the Company”) (TSX:WXI) is pleased to announce that it has completed enrollment and dosing of 50% of the patients in the TectinTM Phase IIb/III clinical study. The Company is preparing an interim analysis which is expected to be completed in the first quarter of 2006. This trial is a randomized double-blind placebo controlled study currently being conducted at 29 sites in Canada for patients suffering from moderate to severe inadequately controlled cancer-related pain. The primary objective of this study is to compare safety and efficacy of subcutaneous treatment of TectinTM versus placebo in reducing the intensity of pain in up to 150 patients with cancer. Additional sites in Chile, where the Company has recently completed an investigators meeting, will participate in the study starting in January with the target of dosing up to 40 patients.
